1. 2020-present: Breast Cancer Heterogeneity in the Era of Molecular Medicine
Mentors: Dr. Matthew Katz MD, Dr. Tatiana Prowell MD, Dr. Stephanie Combs MD, Dr.
Eleonora Teplinsky MD, Dr. Stephanie Graff MD, Dr. Abishek Puri MD
- Contributing to retrospective review article exploring issues related to the clinical relevance of localized breast tumor heterogeneity in regard to systemic and local recurrence patterns, with goal of outlining new areas of research to improve adjuvant treatment and patient outcomes.

2. 2019-present: Radiation Oncology Residency Program Expansion from 1994-2019
Mentors: Dr. Trevor Royce, MD, MS, MPH; Dr. Mudit Chowdhary, MD
- Accumulated and analyzed comprehensive U.S. NRMP and SF residency Match data from 1994-2019, with intent to compare both the rate and magnitude of expansion in Radiation Oncology to all other medical specialties from 2001-present, and to correlate with annual MGMA-derived physician reimbursement. The intent of this project is to potentially inform future Radiation Oncology training program paradigms.

3. 2019-2020: Surrogate Endpoints for Overall Survival in Localized and Recurrent
Prostate Cancer
Mentors: Dr. Daniel E. Spratt, MD; Dr. Laila Gharzai, MD
- Contributed to a meta-analysis of 200+ prostate cancer trials in attempt to identify potential validated clinical intermediate endpoints for overall survival (OS) in localized and recurrent prostate cancer, based on the seminal 2015 ICECaP working group study. If successful, the results from this work will provide a robust surrogate for OS that can expedite the design and conduct of future adjuvant therapy trials of new agents with proven activity in metastatic castrate-resistant prostate cancer.

4. 2019-present: Novel techniques for the Delivery of GRID radiotherapy
Mentors: Dr. Damodar Pokhrel, PhD
- Contributed to expanding database of patients with bulky tumors of varying histology treated with institutionally pioneered “MLC‐based 3D‐crossfire” GRID‐therapy, designed to obviate the need for GRID treatment with traditional high-attenuation Cerrobend blocks or IMRT techniques.

5. 2017-2018: ReCIVA Breath Biopsy HCC Detection Clinical Trial Development
University of Virginia, Department of Radiation Oncology, Hepatobiliary Surgical Oncology
Mentor: Dr. Paul Read MD, PhD
- Helped to design the first U.S. clinical trial to investigate the utility of breath analysis of volatile organic compounds (VOCs) by Field Asymmetrical Ion Mobility (FAIM) spectrometry technology for both non-small cell lung and hepatocellular carcinoma screening detection, and to qualify response to neoadjuvant immunotherapy for these malignancies.

6. 2017-2018: Management of Cytokine Release Syndrome in CAR-T cell therapy
University of Virginia, Department of Pediatric Hematology/Oncology
Mentors: Dr. Daniel W. Lee, MD; Dr. Lara Riegler, MD
- Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma; cytokine release syndrome (CRS) is one of the most clinically important and potentially life-threatening associated side effects. I reported on the indications and early application of CRS treatments, including the anti-IL-6 receptor antibody tocilizumab, according to toxicity grading and clinical manifestations.

7. 2015-2016: Addressing the Clinical Need for Novel Nonopioid Pain Relief in Radiation Cancer Patients
University of Virginia, Department of Radiation Oncology, Hospice & Palliative Medicine
Mentors: Dr. Paul Read MD, PhD; Dr. Julio Silvestre, MD
- Collected data for cross-disciplinary project between Radiation Oncology and Palliative Care teams investigating patient-reported quality of life (QoL) outcomes related to opioid and non-opioid pain relief therapies in terminal cancer patients.

8. 2015-2016: Prognostic and Predictive Factors in Nasopharyngeal, Oropharyngeal, and Hypopharyngeal Radiation Cancer Patients
University of Virginia, Department of Radiation Oncology, Otolaryngology
Mentor: Dr. Paul Read MD, PhD; Dr. David D. Wilson, MD
- Performed retrospective review of 10-year Head and Neck Cancer patient database with analysis of tumor pathology, p16 positivity, EBV positivity, and combined treatment modality (chemoRT, TORS and RT, etc.) on recurrence, overall survival and quality of life (QOL) outcomes.